|
|
|
| Efficacy of Tripterygium Wilfordii Polyglycoside Combined with Taprolimus in the Treatment of Idiopathic Membranous Nephropathy and its Effect on Urinary C5b-9 and IgG4 |
| LIANG Yan, YAN Xiaohui, WANG Xiaoming, et al |
| Shaanxi People's Hospital, Shaanxi Xi'an 710068, China |
|
|
|
|
Abstract Objective: To study the efficacy of tripterygium wilfordii polyglycoside combined with taprolimus in the treatment of idiopathic membranous nephropathy and its effect on urinary Urinary membrane attack complex (c5b-9), immunoglobulin G4 (IgG4). Methods: From Februny 2015 to January 2016, 92 patients with idiopathic membranous nephropathy were divided into observation group and control group according to the order of admission. The control group was treated with tacrolimus on the basis of conventional therapy. The observation group was treated with tripterygium glycosides on the basis of the control group. The clinical efficacy, renal function, urinary C5b-9, IgG4 and sex hormone levels were compared between the two groups. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group [93.48% (43/46) vs 71.27% (33/46)] (P<0.05). The level of serum albumin in the observation group was significantly higher than that in the control group [(34.21 ± 3.87) g vs (24.25 ± 2.42) g] (P<0.05), and the 24h urine protein level was significantly lower than that in the control group [(1.15 ± 0.17) g vs (2.34 ± 0.21) g] (P<0.05). The levels of urinary C5b and IgG4 in the observation group were significantly lower than those in the control group [(45.98 ± 4.32) ng / mg, (65.21 ± 6.54) ug / mmoL vs(1.46 ± 0.21) ng / mg, (6.32 ± 0.69) ug / mmoL] (P<0.05). The levels of SBG, E2 and T in the observation group were significantly higher than those in the control group [(37.54 ± 3.14 nmoL /L, (42.16 ± 4.45) pg /mL, (350.54 ± 35.98) ng/dL vs (26.98 ± 2.87) nmoL / L (35.87 ± 3.76) pg/mL, (287.43 ± 23.76) ng/dL] (P<0.05), FSH level was significantly lower than that of the control group [(6.12 ± 0.65) mIU / mL vs (7.48 ± 0.79) mIU / mL] (P<0.05). Conclusion: Tacrolimus combined with tripterygium wilfordii polyglycoside can be used to treat patients with idiopathic membranous nephropathy, which can effectively reduce the levels of urinary C5b-9 and IgG4, and have little effect on sex hormone levels and good clinical curative effect.
|
|
|
|
|
|
[1] 邱明生,王俊红,王娜,等.环磷酰胺冲击联合激素治疗特发性膜性肾病的预后分析[J].实用医院临床杂志,2017,14(4):88~91.
[2] 董洋,阎磊,李纳,等.不同免疫抑制剂联合糖皮质激素治疗特发性膜性肾病的临床疗效比较[J].中华实用诊断与治疗杂志,2017,31(10):1017~1019.
[3] 佚名.黄葵胶囊联合他克莫司和泼尼松治疗特发性膜性肾病的疗效观察[J].现代药物与临床,2017,32(6):1061~1064.
[4] 佚名.环孢素联合糖皮质激素治疗特发性膜性肾病的远期疗效及安全性研究[J].河北医学,2017,23(7):1202~1206.
[5] 徐毅芳,徐莹.他克莫司联合糖皮质激素治疗特发性膜性肾病的临床研究[J].中国现代医生,2017,55(12):122~124.
[6] 张胜志.来氟米特、雷公藤多苷联合小剂量激素治疗特发性膜性肾病的疗效[J].北方药学,2017,14(2):101.
[7] 余霄,欧阳晓琴,姜宝霞,等.雷公藤多苷对特发性膜性肾病患者抗磷脂酶A2受体抗体的影响[J].世界中医药,2018,13(5):144~147.
[8] 刘晓斌,张秋花,陈勇,等.特发性膜性肾病临床、病理特点及M型磷脂酶A2受体表达的相关分析[J].实用医学杂志,2017,33(15):2520~2524. |
|
|
|
2020, Vol. 26 
